Feasibility Study on Measuring Selected Proteins in Malignant Melanoma Tissue by SRM Quantification.
In J Proteome Res, 03 Mar 2014
In a pilot study applying the SRM assay, the tissue expression of nine selected proteins proteins (complement 3 (C3), T-cell surface glycoprotein CD3 epsilon chain E (CD3E), dermatopontin, minichromosome maintenance complex component (MCM4), premelanosome protein (PMEL), S100 calcium binding protein A8 (S100A8), S100 calcium binding protein A13 (S100A13), transgelin-2 and S100B), was quantified in a small cohort of metastatic malignant melanoma patients.
Anti-CD3 recombinant diphtheria immunotoxin therapy of cutaneous T cell lymphoma.
Temple, United States. In Curr Drug Targets, 2009
The recombinant CD3 immunotoxin, A-dmDT(390)-bisFv(UCHT1), composed of the catalytic and translocation domains of diphtheria toxin fused to two single chain Fv fragments of an anti-CD3epsilon monoclonal antibody was administered to five patients with cutaneous T cell lymphoma (CTCL) by eight 15 min intravenous infusions over four days.
Intravascular cytotoxic T-cell lymphoma: A case report and review of the literature.
Boston, United States. In J Am Acad Dermatol, 2008
A 62-year-old male presented with erythematous patches and plaques on the lower extremities, and a biopsy revealed IVL with an activated cytotoxic phenotype (CD56(+), perforin+, granzyme B+, TIA-1+, CD3epsilon(+), CD20(-), CD4(-), CD8(-), CD5(-), and T-cell receptor [TCR] betaF1(-)), consistent with either NK-cell or T-cell origin.
Human monoclonal antibodies from transgenic mice.
Milpitas, United States. In Handb Exp Pharmacol, 2007
Since the 1986 regulatory approval of muromonomab-CD3, a mouse monoclonal antibody (MAb) directed against the T cell CD3epsilon antigen, MAbs have become an increasingly important class of therapeutic compounds in a variety of disease areas ranging from cancer and autoimmune indications to infectious and cardiac diseases.